BioXcel Therapeutics, Inc. (NASDAQ:BTAI) Q3 2022 Earnings Conference Call November 10, 2022 8:30 AM ET
Company Participants
Vimal Mehta - Chief Executive Officer & Founder
Matt Wiley - Chief Commercial Officer
Richard Steinhart - Chief Financial Officer
Rob Risinger - Chief Medical Officer, Neuroscience
Vincent O’Neill - Chief Medical Officer, Oncology
Conference Call Participants
Greg Harrison - Bank of America
Colin Bristow - UBS
Yatin Suneja - Guggenheim Partners
Graig Suvannavejh - Mizuho Securities
Ram Selvaraju - H.C. Wainwright
Corinne Jenkins - Goldman Sachs
Operator
Good morning, and welcome to the BioXcel Therapeutics Third Quarter 2022 Financial Results Conference Call. At this time, all participants are in a listen-only mode. [Operator Instructions] After the presentation, there will be a question-and-answer session. [Operator Instructions]
Just to remind everyone, certain matters discussed in today's conference call and/or answers that may be given to questions asked are forward-looking statements that are subject to risks and uncertainties related to future events and/or the future financial or business performance of the company.
Actual results could differ materially from those anticipated in these forward-looking statements. Risk factors that may affect future results are detailed in the company's quarterly report on Form 10-Q for the quarter ended June 30, 2022 which can be found at www.BioXceltherapeutics.com or on www.sec.gov, which will be updated in its quarterly report on Form 10-Q for the quarter ended September 30, 2022. As a reminder, today's conference is being recorded.
Joining us on today's call are Dr. Vimal Mehta, Chief Executive Officer; Richard Steinhart, Chief Financial Officer; Matt Wiley, Chief Commercial Officer; Dr. Rob Risinger, Chief Medical Officer of Neuroscience; Dr. Frank Yocca, Chief Scientific Officer; and Dr. Vince O’Neill, Chief Medical Officer of Oncology.
It is now my pleasure to turn the call over to Dr. Mehta, the CEO and Founder of BioXcel Therapeutics. Please go ahead.
Vimal Mehta
Thank you, operator. Welcome everyone and thank you for joining our call today to discuss BioXcel Therapeutics financial performance and business highlights. The third quarter of 2022 marked a pivotal moment in the history of BioXcel Therapeutics. In the last few months, we have transitioned to a commercial organization and successfully launched IGALMI. We have made tremendous progress across all facets of our business and are very excited for 2023 and beyond.
We continue to fully execute on our land and expense strategy for lead program, BXCL501 to build our neuroscience agitation franchise. In that regard, we have multiple pivotal data readouts from our ongoing trials expected in the first half of 2023. We believe this will allow us to capitalize on the $15 billion agitation market opportunity. This consists of 139 million episodes in total for our first three indications, including bipolar disorder, schizophrenia and Alzheimer's. Agitation is an under diagnosed and underserved market that has not seen treatment innovation in nearly a decade.